



Company profile

In brief

Fresenius Biotech – a subsidiary company of the Fresenius Health Care Group – is focused on the development, marketing and commercialization of biopharmaceuticals in the fields of oncology and transplantation medicine. Our current research and development activities are primarily concentrated on the clinical development of immunotherapeutic products based on innovative antibody technologies. The company also holds majority interest in the “European Institute for Research and Development of Transplantation Strategies” (EUFETS AG).

Facts & data

- Founded in 2003
- Headquartered in Gräfelfing near Munich, Germany
- Approx. 200 employees
- Executive management:
 Dr. Bernhard Ehmer (Chief Executive Officer)
 Dr. Axel Wiest (Chief Operating Officer)
 Dr. Hans Bochtler (Chief Scientific Officer)
 Oliver Maschinsky (Chief Financial Officer)

Products and research focuses

Project	Phase of development					
	R&D	Preclinical	Phase I	Phase II	Phase III	Commercialization & Phase IV
ATG	■	■	■	■	■	■
ATG in Stem Cell Transplantation	■	■	■	■	■	
ATG USA	■	■	■	■	■	
Malignant Ascites (catumaxomab)	■	■	■	■	■	
Ovarian Cancer (catumaxomab)	■	■	■	■		
Gastric Cancer (catumaxomab)	■	■	■	■		
Breast Cancer (ertumaxomab)	■	■	■	■		
Chronic Lymphocytic Leukemia (FBT-A05)	■	■	■			



Oncology: trifunctional antibodies

Fresenius Biotech develops trifunctional antibodies for use in targeted cancer treatment in cooperation with the biotechnology firm TRION Pharma, Munich. Within this partnership, Fresenius Biotech is in charge of clinical research and development as well as marketing & sales. The postulated mode of action of these specific monoclonal antibodies is based on linking cancer cells directly to cells of the body's own immune system, thereby inducing the destruction of the tumor cells. The anti-tumor effect of trifunctional antibodies is being investigated for a number of indications: malignant ascites caused by various primary tumors, ovarian cancer, gastric cancer, breast cancer and B-cell malignancies.

Immunology: antibody-based immunosuppressive

ATG-Fresenius S (ATG) is a drug made of polyclonal antibodies used to suppress unwanted immune reactions. ATG has been used successfully in organ transplantation for over 25 years in more than 60 countries.

With the objective to expand the range of approved indications for ATG, a Phase III study is currently underway to examine its effects on the life-threatening "graft-versus-host disease" following stem cell/bone marrow transplantation. The goal of the treatment is to prevent the donor's T-cells from attacking the recipient's own cells.

Manufacturing of products for cell or gene therapy

The European Institute for Research and Development of Transplantation Strategies (EUFETS AG) is a competence center for gene and cell therapy where Fresenius holds a majority interest. EUFETS can offer a comprehensive know-how for the development and production of cell therapeutics, retroviral vectors and the genetic modification of primary cells or cell lines. The GMP services include a broad spectrum from process development and validation up to the production of material for clinical trials as well as for the market. In addition, EUFETS can provide cell based *in vitro* safety and efficacy studies under GLP conditions as well as support of clinical studies.